帕利哌酮缓释片治疗精神分裂症的疗效观察

摘 要 目的：观察帕利哌酮缓释片治疗精神分裂症的疗效和预后。方法: 精神分裂症患者72例按入院先后顺序分为观察组(n=35)和对照组(n=37)。观察组给予帕利哌酮缓释片治疗，对照组给予利培酮片治疗。两组均治疗8周。采用阳性和阴性症状量表(PANSS)评价两组患者的治疗效果，并比较两组患者社会功能缺陷量表(SDSS)及预后。 结果: 治疗后2周末开始，两组患者的PANSS总分、阳性症状评分、阴性症状评分以及一般病理症状评分均较治疗前明显降低(P<0.05)，且观察组各项评分均明显低于同期对照组(P<0.05)。治疗后两组患者的SDSS评分均较治疗前明显降低(P<0.05)，且观察组明显低于对照组(P<0.05)。观察组总有效率为94.3%，明显高于对照组的67.6%(P<0.05)。观察组焦虑、静坐不能等不良反应发生率和总药品不良反应发生率均明显低于对照组(P<0.05)。结论:帕利哌酮可有效缓解精神分裂症患者的病情，起效快、不良反应少，值得临床推广使用。

Therapeutic Effect of Paliperidone Extended release Tablets in Schizophrenia Patients

ABSTRACT Objective: To investigate the curative effect and prognosis of schizophrenia patients treated with paliperidone extended release tablets. Methods: Totally 72 cases of patients with schizophrenia were divided into the observation group (n=35) and the control group (n=37) according to the order of admission.The obsevation group was treated with paliperidone extended release tablets, while the controll group was treated with risperidone tablets, and both groups were treated for 8 weeks. The positive and negative syndrome scale(PANSS) was used to assess the effect of the two groups, the social function defect scale(SDSS) and prognosis of the two groups were compared.Results:After the 2 week treatment, the PANSS score, positive symptom score, negative symptom score and general symptom score were all decreased in the two groups when compared with those before the treatment(P<0.05),and the scores in the observation group were lower than those in the controll group(P<0.05). After the treatment, the SDSS was significantly reduced in the two groups when compared with that before the treatment(P<0.05), and the reduction in the observation group was more notable than that in the control group(P<0.05). The total effective rate of the observation group was 94.3%, which was higher than that (67.6%) of the control group (P<0.05). The incidence of adverse reactions, such as anxiety and akathisia, and the total adverse drug reactions in the observation group were both lower than those in the control group (P<0.05).Conclusion:Paliperidone extended release tablets can effectively relieve suffering from schizophrenia with quick effect, few adverse reactions, high safety and good effect, which is worthy of promotion in clinical use.